Showing results (1-10 of 131) with videos related to
Sort By:
Pageof 14
Advances in Experimental Medicine and Biology|July 21, 2021
CXCL12 Signaling in the Tumor MicroenvironmentLuigi Portella, Anna Maria Bello, Stefania ScalaSeminars in Oncology|August 7, 2019
Ionizing radiation effects on the tumor microenvironmentLuigi Portella, Stefania ScalaPlos One|December 19, 2024
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cellsDaniela Russo, Anna Spina, Luigi Portella, et al.Chemical Biology & Drug Design|April 26, 2012
The N-terminal region of CXCL11 as structural template for CXCR3 molecular recognition: synthesis, conformational analysis, and binding studiesPasquale Palladino, Luigi Portella, Giovanni Colonna, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2015
Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor MicroenvironmentStefania ScalaMolecular Biosystems|August 12, 2015
Intrinsically disordered amphiphilic peptides as potential targets in drug delivery vehiclesMarian Vincenzi, Antonella Accardo, Susan Costantini, et al.British Journal of Cancer|May 4, 2024
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patientsSara Santagata, Giuseppina Rea, Anna Maria Bello, et al.Scientific Reports|June 2, 2017
A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumorsSara Santagata, Luigi Portella, Maria Napolitano, et al.International Journal of Molecular Sciences|June 2, 2015
Conformational ensembles explored dynamically from disordered peptides targeting chemokine receptor CXCR4Marian Vincenzi, Susan Costantini, Stefania Scala, et al.Frontiers in Immunology|June 24, 2020
Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label DrugsStefania Scala, Roberto PacelliPageof 14